一時的な経静脈ダイヤフラム ペーシングと人工呼吸器からの離脱のための標準治療を比較するプロトコル (RESCUE 3)
人工呼吸器からの離脱に失敗した患者における Lungpacer ダイアフラム ペーシング療法システムの安全で効果的な性能を評価するための無作為化、制御、非盲検、多施設臨床試験。
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
調査の概要
状態
詳細な説明
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
California
-
Stanford、California、アメリカ、94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- University of Florida, Shands
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush University Medical Center
-
Chicago、Illinois、アメリカ、60611
- Northwestern University Feinberg School of Medicine
-
Chicago、Illinois、アメリカ、60612
- U of Illinois at Chicago
-
Hines、Illinois、アメリカ、60141
- Edward Hines VA Hospital
-
Maywood、Illinois、アメリカ、60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University Health Methodist Hospital
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- University of Louisville
-
-
Massachusetts
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55407
- Minneapolis Heart Institute Foundation
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68124
- CHI Health Creighton University Medical Center - Bergan Mercy
-
-
New Jersey
-
Englewood、New Jersey、アメリカ、07631
- Englewood Hospital Medical Center
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267
- University of Cincinnati
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Columbus、Ohio、アメリカ、43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19140
- Temple University Hospital
-
-
Rhode Island
-
Warwick、Rhode Island、アメリカ、02886
- Kent County Memorial Hospital
-
-
South Carolina
-
Columbia、South Carolina、アメリカ、29203
- Prisma Health Baptist Hospital
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- University of Texas Southwestern, Zale Lipshy Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84132
- University of Utah
-
-
-
-
-
Berlin、ドイツ、10117
- Berlin Charite Mitte
-
Essen、ドイツ、45276
- KEM Essen
-
Löwenstein、ドイツ、74245
- SLK Löwenstein
-
Nuremberg、ドイツ、90419
- Nürnberg Klinikum Nord
-
Schmallenberg、ドイツ、57392
- FKKG Schmallenberg
-
Solingen、ドイツ、42699
- Solingen Krankenhaus Bethanien
-
-
Mecklenburg-Vorpommern
-
Greifswald、Mecklenburg-Vorpommern、ドイツ、17475
- Universitätsmedizin Greifswald
-
-
-
-
-
Angers、フランス、49933
- CHU Angers
-
Montpellier、フランス、34295
- CHU Montpellier
-
Paris、フランス、75651
- Hôpital La Pitié-Salpêtrière
-
Strasbourg、フランス、67091
- CHU Strasbourg
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Are 18 years or older, and,
- Have been mechanically ventilated for ≥96 hours (4 days), and,
- Have satisfied the Readiness-to-Wean criteria, and,
- Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).
Exclusion Criteria:
- Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
- Invasive mechanical ventilation >90 days;
- Currently on extracorporeal membrane oxygenation (ECMO);
- Weaning failure due to hypervolemia;
- Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
- Clinically overt congestive heart failure that is preventing weaning;
- Currently being treated with neuromuscular blockade;
- Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
- Pre-existing severe chronic pulmonary fibrosis;
- Pleural effusions occupying greater than one third of the pleural space on either side;
- BMI >45 kg/m2;
- Known or suspected phrenic nerve paralysis;
- Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
- Current hemodynamic instability, sepsis or septic shock;
- Prior bacteremia reported within the last 48 hours;
- Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
- Known or suspected to be pregnant or lactating;
- Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Treatment
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation. |
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
他の名前:
|
|
介入なし:Control
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Successful Weaning
時間枠:Through Day 30
|
Cumulative percentage of subjects successfully weaned by Day 30. |
Through Day 30
|
|
Adverse Event Profile
時間枠:30 days
|
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined. |
30 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Days on Mechanical Ventilation (MV)
時間枠:Successful weaning or Day 30
|
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control. |
Successful weaning or Day 30
|
|
Maximal Inspiratory Pressure (MIP) Change
時間枠:Baseline last available measure through Day 30.
|
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control. |
Baseline last available measure through Day 30.
|
|
Rapid Shallow Breathing Index (RSBI) Change
時間枠:Baseline to last available measure through Day 30.
|
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement. |
Baseline to last available measure through Day 30.
|
|
Survival
時間枠:30 days
|
Cumulative percentage of subjects who survived through Day 30. |
30 days
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Re-instatements of MV (After Successful Weaning) Through Day 30.
時間枠:Through Day 30.
|
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group. |
Through Day 30.
|
|
Tracheotomy After Randomization
時間枠:Through 30 days
|
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group. |
Through 30 days
|
|
ICU Discharges to Day 30.
時間枠:through 30 days
|
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
|
Hospital Discharges to Day 30.
時間枠:through 30 days
|
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- P-300
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。